Maintenance Therapy

Maintenance medication may help reduce COPD symptoms

Clinical guidelines recommend maintenance treatment with long-acting bronchodilators in appropriate patients1,2
  • GOLD COPD treatment strategies include the use of a long-acting antimuscarinic antagonist (LAMA), for bronchodilation.1
  • The American Thoracic Society recommends clinicians prescribe monotherapy using either long-acting inhaled anticholinergics or long-acting inhaled beta-agonists for symptomatic patients with COPD and FEV1 <60% predicted2

GOLD does not endorse any specific treatments

GOLD=Global Initiative for Chronic Obstructive Lung Disease.

Many patients receive little or no COPD maintenance treatment for their symptoms

According to the CDC, nearly 15.7 million Americans have been diagnosed with COPD, and it is estimated that nearly as many remain undiagnosed and therefore untreated.3


Of the diagnosed population, more than 66% of patients with COPD covered by private insurance do not receive maintenance therapy4 despite their chronic symptoms.* 

*From a retrospective analysis of US managed care and Medicare patients covered by Medicare Part B or private insurance.


 

Consider a LAMA option for COPD maintenance therapy – shown to reduce COPD symptoms when used appropriately.1

 
 

References:
1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017.
2. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191. 
3. Chronic Obstructive Pulmonary Disease (COPD). Centers for Disease Control and Prevention website. https://www.cdc.gov/copd/index.html. Accessed June 30, 2017.
4. Make B, Dutro MP, Paulose-Ram R, Marton JP, Mapel DW. Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients. Int J Chronic Obstruc Pulmon Dis. 2012;7:1-9.

Important Safety Information & Indication

Important Safety Information

SEEBRI NEOHALER is contraindicated in patients with a hypersensitivity to glycopyrrolate or to any of the ingredients.

SEEBRI NEOHALER should not be initiated in patients with acutely deteriorating or potentially life-threatening episodes of COPD or used as rescue therapy for acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, SEEBRI NEOHALER can produce paradoxical bronchospasm that may be life threatening. If paradoxical bronchospasm occurs following dosing with SEEBRI NEOHALER, it should be treated immediately with an inhaled, short-acting bronchodilator; SEEBRI NEOHALER should be discontinued immediately and alternative therapy instituted.

Immediate hypersensitivity reactions have been reported with SEEBRI NEOHALER. If signs occur, discontinue immediately and institute alternative therapy. SEEBRI NEOHALER should be used with caution in patients with severe hypersensitivity to milk proteins.

SEEBRI NEOHALER should be used with caution in patients with narrow-angle glaucoma and in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema) and of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Patients should be instructed to consult a physician immediately should any of these signs or symptoms develop.

The most common adverse events reported in ≥1% of patients taking SEEBRI NEOHALER, and occurring more frequently than in patients taking placebo, were upper respiratory tract infection (3.4% vs 2.3%), nasopharyngitis (2.1% vs 1.9%), oropharyngeal pain (1.8% vs 1.2%), urinary tract infection (1.4% vs 1.3%), and sinusitis (1.4% vs 0.7%).

SEEBRI capsules must not be swallowed as the intended effects on the lungs will not be obtained. SEEBRI capsules are only for oral inhalation and should only be used with the NEOHALER device.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see full Prescribing Information and Patient Information for SEEBRI NEOHALER.

Indication

SEEBRITM NEOHALER® (glycopyrrolate) is an anticholinergic indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.